|55 Kenosia Avenue
Danbury, CT 06810
Toll Free: 1.800.999.6673
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
Copyright 1988, 1989, 2003
Two types of hyperprolinemia are recognized by physicians and clinical researchers. Each represents an inherited inborn error of metabolism involving the amino acid, proline. Proline is abundant in nature and readily found in a variety of foods.
Hyperprolinemia Type I (HP-I) is characterized by abnormally high levels of proline in the blood. The high level of blood proline is the result of a deficiency of the enzyme proline oxidase, which is essential to the normal breakdown (metabolism) of proline. There are often no clinical manifestations of HP-1.
Hyperprolinemia II (HP-II) results from the deficiency of another enzyme and also results in high blood proline levels, as well as other more severe clinical manifestations than are seen in HP-I. Mild mental retardation and convulsions are commonly associated with HP-II.
Hyperprolinemia Type I is the result of proline oxidase deficiency and is characterized by an abnormally high proline blood level. Levels of the amino acids hydroxyproline and glycine in the blood are also higher than normal. Some clinicians believe that kidney abnormalities may be associated with HP-I, although this is disputed. The signs and symptoms of HP-I, other than the high levels of amino acids in the blood and urine, are vague. Often, this disorder is described as benign.
Hyperprolinemia Type I is an autosomal recessive disorder. The gene involved is located on the long arm of chromosome 22. Chromosomes, which are present in the nucleus of human cells, carry the genetic characteristics of each individual. Pairs of human chromosomes are numbered from 1 through 22, with an unequal 23rd pair of X and Y chromosomes for males, and two X chromosomes for females. Each chromosome has a short arm designated as "p" and a long arm identified by the letter "q". Chromosomes are further subdivided into many bands that are numbered. For example, chromosome 22q11.2 refers to band 11 on the long arm of chromosome 22.
Recessive genetic disorders occur when an individual inherits the same abnormal gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and, therefore, have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females.
All individuals carry a few abnormal genes. Parents who are close relatives (consanguineous) have a higher chance than unrelated parents to both carry the same abnormal gene, which increases the risk to have children with a recessive genetic disorder.
Hyperprolinemia Type I is a very rare disorder that is present at birth. It affects males and females in equal numbers.
Symptoms of the following disorder are similar to those of Hyperprolinemia Type I.
I. Comparisons may be useful for a differential diagnosis:
Hyperprolinemia Type II is a very rare hereditary condition characterized by a level of proline in the blood greater than that in Type I Hyperprolinemia. In addition, delta-1-pyrroline-5-carboxylate is excreted in the urine. Mental retardation and seizures may also occur. (For more information, choose "Hyperprolinemia Type II" as your search term in the Rare Disease Database.)
HP-I is recognized by elevated blood proline levels. (The normal level is approximately 450 units, but people with HP-1 may have levels of 1900 to 2000 units.) Often, the diagnosis is made by exclusion. After failure to arrive at a diagnosis by other means, a blood proline level is ordered. The result confirms the diagnosis.
Because proline is so widespread among foods, attempts to control blood proline levels by restrictive dieting have not succeeded. Because the medical consequences of this particular inborn error of metabolism appear to be modest or inconsequential, many physicians do not take an aggressive approach toward treatment.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
(To become a member of NORD, an organization must meet established criteria and be approved by the NORD Board of Directors. If you're interested in becoming a member, please contact Susan Olivo, Membership Manager, at email@example.com.)
Phang JM, Yeh GC, Scriver CR. In: Scriver CR, Beaudet AL, Sly WS, et al. Eds. The Metabolic Molecular Basis of Inherited Disease. 7th ed. McGraw-Hill Companies. New York, NY; 1995:1125-26; 1343-44.
Jacquet H, Raux G, Thibaut F, et al. PRODH mutations and hyperprolinemia ina subset of schizophrenic patients. Hum Mol Genet. 2002;11:2243-49.
Humberclaude V, Rivier F, Roubertie A, et al. Is hyperprolinemia type I actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance. J Child Neurol. 2001;16:622-23.
Goodman BK, Rutberg J, Lin WW, et al. Hyperprolinemia in patients with deletion (22)(q11.2) syndrome. J Inherit Metab Dis. 2000;23:847-48.
Shivananda, Christopher R, Kumar P. Type I hyperprolinemia. Indian J Pediatr. 2000;67:541-43.
Oyanagi K, Tsuchiyama A, Itakura Y, et al. Clinical, biochemical and enzymatic studies in type I hyperprolinemia associated with chromosomal activity. Tohoku J Exp Med. 1987;151:465-75.
FROM THE INTERNET
McKusick VA, Ed. Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Entry Number; 239500: Last Edit Date; 9/10/2002.
Report last updated: 2008/03/23 00:00:00 GMT+0